Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey].
Lorcet M, Lortholary A, Kurtz JE, Berton-Rigaud D, Fabbro M, De La Motte Rouge T, Kaminsky-Forrett MC, Floquet A, Freyer G, Combe P, Dohollou N, Kalbacher E, Despax R, Largillier R, Hardy Bessard AC, Gane N, Sehouli J, Oskay-Oezcelik G, Licaj I, Ray-Coquard I, Joly Lobbedez F. Lorcet M, et al. Among authors: de la motte rouge t. Bull Cancer. 2018 May;105(5):465-474. doi: 10.1016/j.bulcan.2018.01.015. Epub 2018 Mar 12. Bull Cancer. 2018. PMID: 29544693 French.
[Cannabis and cancer].
Vignot S, Besse B, de la Motte Rouge T, Massard C, Spano JP, Karila L. Vignot S, et al. Among authors: de la motte rouge t. Bull Cancer. 2006 Feb;93(2):163-70. Bull Cancer. 2006. PMID: 16517414 Free article. Review. French.
[Targeted therapy in locally and metastatic recurrent cervical cancers].
Geiss R, De La Motte Rouge T, Dubot C, Leary A, Lhommé C, Pautier P, Scholl S, Rodrigues MJ. Geiss R, et al. Among authors: de la motte rouge t. Bull Cancer. 2014 Jul-Aug;101(7-8):748-55. doi: 10.1684/bdc.2014.1949. Bull Cancer. 2014. PMID: 25091657 Review. French.
Cancer de l’ovaire : la rechute précoce.
Pautier P, Kalbacher E, de la Motte Rouge T, Bonnetain F, Lesoin A. Pautier P, et al. Among authors: de la motte rouge t. Bull Cancer. 2017 May;104 Suppl 1:S32-S38. doi: 10.1016/S0007-4551(17)30160-1. Bull Cancer. 2017. PMID: 28625313 French.
[Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer].
Rousset-Jablonski C, Selle F, Adda-Herzog E, Planchamp F, Selleret L, Pomel C, Chabbert-Buffet N, Daraï E, Pautier P, Trémollières F, Guyon F, Rouzier R, Laurence V, Chopin N, Faure-Conter C, Bentivegna E, Vacher-Lavenu MC, Lhomme C, Floquet A, Treilleux I, Lecuru F, Gouy S, Kalbacher E, Genestie C, de la Motte Rouge T, Ferron G, Devouassoux-Shisheboran M, Kurtz JE, Namer M, Joly F, Pujade-Lauraine E, Grynberg M, Querleu D, Morice P, Gompel A, Ray-Coquard I. Rousset-Jablonski C, et al. Among authors: de la motte rouge t. Bull Cancer. 2018 Mar;105(3):299-314. doi: 10.1016/j.bulcan.2017.10.032. Bull Cancer. 2018. PMID: 29397916 French.
[Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa].
Lavoue V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, Bendifallah S, Bolze PA, Bonnet F, Bourgin C, Chabbert-Buffet N, Collinet P, Courbiere B, De la Motte Rouge T, Devouassoux-Shisheboran M, Falandry C, Ferron G, Fournier L, Gladieff L, Golfier F, Gouy S, Guyon F, Lambaudie E, Leary A, Lecuru F, Lefrere-Belda MA, Leblanc E, Lemoine A, Narducci F, Ouldamer L, Pautier P, Planchamp F, Pouget N, Ray-Coquard I, Rousset-Jablonski C, Senechal-Davin C, Touboul C, Thomassin-Naggara I, Uzan C, You B, Daraï E. Lavoue V, et al. Among authors: de la motte rouge t. Bull Cancer. 2019 Apr;106(4):354-370. doi: 10.1016/j.bulcan.2019.01.014. Epub 2019 Mar 6. Bull Cancer. 2019. PMID: 30850152 Free article. Review. French.
Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.
Labidi-Galy SI, de La Motte Rouge T, Derbel O, Wolfer A, Kalbacher E, Olivier T, Combes JD, Heimgartner-Hu K, Tredan O, Guevara H, Heudel PE, Reverdy T, Bazan F, Heinzelmann-Schwarz V, Fehr M, de Castelbajac V, Vaflard P, Crivelli L, Bonadona V, Viassolo V, Buisson A, Golmard L, Rodrigues M, Ray-Coquard I. Labidi-Galy SI, et al. Among authors: de castelbajac v, de la motte rouge t. Gynecol Oncol. 2019 Nov;155(2):262-269. doi: 10.1016/j.ygyno.2019.09.008. Epub 2019 Oct 8. Gynecol Oncol. 2019. PMID: 31604666
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators. Poveda A, et al. Lancet Oncol. 2021 May;22(5):620-631. doi: 10.1016/S1470-2045(21)00073-5. Epub 2021 Mar 18. Lancet Oncol. 2021. PMID: 33743851 Clinical Trial.
111 results